Los Angeles Capital Management’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-492
| Closed | -$34.3K | – | 2573 |
|
|
2025
Q4 | $34.3K | Buy |
+492
| New | +$31.8K | ﹤0.01% | 1704 |
|
|
2024
Q4 | – | Sell |
-14,376
| Closed | -$660K | – | 1227 |
|
|
2024
Q3 | $660K | Buy |
+14,376
| New | +$624K | ﹤0.01% | 784 |
|
|
2024
Q2 | – | Sell |
-56,997
| Closed | -$1.45M | – | 1263 |
|
|
2024
Q1 | $1.45M | Sell |
56,997
-3,290
| -5% | -$51.6K | 0.01% | 576 |
|
|
2023
Q4 | $546K | Buy |
60,287
+1,030
| +2% | +$6.88K | ﹤0.01% | 841 |
|
|
2023
Q3 | $378K | Buy |
+59,257
| New | +$511K | ﹤0.01% | 903 |
|
|
2022
Q4 | – | Sell |
-12,025
| Closed | -$196K | – | 1268 |
|
|
2022
Q3 | $196K | Sell |
12,025
-5,670
| -32% | -$108K | ﹤0.01% | 1175 |
|
|
2022
Q2 | $257K | Sell |
17,695
-36,679
| -67% | -$546K | ﹤0.01% | 1194 |
|
|
2022
Q1 | $1M | Hold |
54,374
| – | – | ﹤0.01% | 760 |
|
|
2021
Q4 | $1.29M | Hold |
54,374
| – | – | ﹤0.01% | 635 |
|
|
2021
Q3 | $1.34M | Sell |
54,374
-6,000
| -10% | -$130K | 0.01% | 652 |
|
|
2021
Q2 | $1.49M | Sell |
60,374
-5,990
| -9% | -$139K | 0.01% | 679 |
|
|
2021
Q1 | $1.45M | Buy |
66,364
+1,826
| +3% | +$44.7K | 0.01% | 741 |
|
|
2020
Q4 | $1.65M | Buy |
+64,538
| New | +$1.88M | 0.01% | 731 |
|
Other funds holding RNAM
Los Angeles Capital Management's RNAM Position: Q1 2026 in Review
Los Angeles Capital Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 492 shares — an estimated $34.3K sold.
Los Angeles Capital Management first reported a position in RNAM in Q4 2020 and held it in 13 quarters. The position peaked at $1.65M in Q4 2020. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Los Angeles Capital Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Los Angeles Capital Management sold 492 Avidity Biosciences shares in Q1 2026, an estimated $34.3K.
- Los Angeles Capital Management first reported a position in Avidity Biosciences in Q4 2020 and held it in 13 quarters.
- Los Angeles Capital Management's Avidity Biosciences position peaked at $1.65M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.